The product is formulated with Lacticaseibacillus rhamnosus GG (formerly Lactobacillus rhamnosus GG) along with ADM’s Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) strain. BPL1 is supported by a portfolio of pre-clinical and clinical evidence demonstrating its potential metabolic health and weight management benefits.
Among the studies supporting the strains efficacy is a three-month randomized, parallel, double-blind, placebo-controlled trial that was published in 2019 in the International Journal of Obesity. The study, which included 126 obese adults, found that supplementation with either live or heat-killed BPL1 led to significant reductions in waist circumference (-1.75 cm in the live and -1.84 cm heat-killed groups) and the live bacterium produced statistically significant reductions in BMI versus both its baseline levels and the placebo group.
“As this is the first Culturelle product to target metabolic health and weight management, we’re proud to say it’s formulated with BPL1 and highlight the robust science that supports it. This has been possible thanks to our strong partnership with ADM, and we’re looking forward to exploring further opportunities together,” said Eric Bianco, Brand Lead – North America at Culturelle.
The Culturelle Metabolism + Weight Management product is currently available in the United States and Canada.
Mechanism of action
Commenting on the specifics of how the strain’s effects, June Lin, Global Vice President, Marketing, Health & Wellness, ADM, told NutraIngredients-USA that three years of work by an interdisciplinary team of 12 ADM scientists identified lipoteichoic acid (LTA) as the compound responsible for BPL1’s functionality.